Truist Financial Reaffirms Their Buy Rating on Progyny (PGNY)
Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $48 Price Target
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Progyny (PGNY) and Protagonist Therapeutics (PTGX)
Buy Rating Affirmed for Progyny Despite Seasonal Dip: Long-term Growth and Solid Fundamentals Justify Premium Valuation
Progyny: A Positive Growth Outlook Justifies Buy Rating Despite Q4 Miss
Keybanc Maintains Overweight on Progyny, Lowers Price Target to $43
Progyny Analyst Ratings
Progyny (PGNY) Receives a Buy From Barclays
Progyny Analyst Ratings
Progyny (PGNY) Receives a Buy From Truist Financial
Truist Financial Keeps Their Buy Rating on Progyny (PGNY)
BTIG Reaffirms Their Buy Rating on Progyny (PGNY)
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Medtronic (MDT) and Progyny (PGNY)
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Progyny (PGNY) and IQVIA Holdings (IQV)
Progyny Analyst Ratings
Progyny's Strong Growth and Momentum: An Optimistic Buy Rating Despite Macro Challenges and Price Adjustment
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY), DaVita (DVA) and Demant (OtherWILLF)
Progyny's Robust Performance and Strong Market Demand Drive Buy Rating: An Analysis of Q3 2023
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Progyny (PGNY) and Exelixis (EXEL)
JP Morgan Maintains Overweight on Progyny, Lowers Price Target to $57
No Data